問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Radiology

Division of Radiation Therapy

Taoyuan Psychiatric Center,MOHW (在職)

Division of Psychiatry

Show-Chwan Memorial Hospital (在職)

Division of Cardiovascular Diseases

MacKay Memorial Hospital (在職)

Division of Urology

Division of Hematology & Oncology

Division of Hematology & Oncology

MacKay Memorial Hospital

Division of Hematology & Oncology

更新時間:2023-09-19

陳建志
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

40Cases

2020-08-14 - 2027-07-24

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-10-15 - 2024-06-13

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting5Sites

Terminated1Sites

2021-10-01 - 2025-04-18

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting5Sites

Terminated5Sites

2021-04-01 - 2024-12-18

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting6Sites

Terminated4Sites

2019-07-15 - 2020-12-31

Phase II

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Terminated2Sites

2024-04-01 - 2028-01-31

Phase I

Active
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

Terminated1Sites

2024-04-15 - 2025-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2008-04-01 - 2010-05-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients
  • Condition/Disease

    Advanced Nasopharyngeal Carcinoma

  • Test Drug

    Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

1 2 3 4